telisotuzumab
abbvie
['telisotuzumab', 'abbvie']
 2022 updates:
at the ongoing #asco 2022 meeting, presented an interim analysis from the phase i &amp; phase ii luminosity trial of #telisotuzumab vedotin (teliso-v). visit for more at: #asco #asco02022 #oncology #cancer 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry